To include your compound in the COVID-19 Resource Center, submit it here.

Fabrazyme agalsidase beta enzyme replacement therapy regulatory update

The FDA completed its review of GENZ's BLA for Fabrazyme to treat Fabry disease,

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE